Key Performance
More- Earnings Score: 80
- Momentum Score: 57
- True Yield: N/A
- Financial Health Score: 94
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates
AnaptysBio (ANAB) reported a quarterly loss of $0.11 per share, beating consensus estimates of $0.46 loss, with a 76% earnings surprise. However, the company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends. The Medical - Biomedical and Genetics industry ranks in the bottom 32% of sectors. Nurix Therapeutics (NRIX) is expected to report results with a projected loss of $0.56 per share but with significant revenue growth of 1665.8% year-over-year.
09/21/2026, 5:35 PM • Zacks
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim
A Delaware Chancery Court dismissed Tesaro's (GSK subsidiary) anticipatory breach of contract claim against AnaptysBio, rejecting requests for royalty reductions on Jemperli. The ruling affirms Anaptys has not repudiated the collaboration agreement and validates the company's efforts to protect its contractual rights. A trial is scheduled for July 14-17, 2026, where Anaptys will pursue claims that Tesaro/GSK materially breached the agreement and seek potential reversion of Jemperli.
04/24/2026, 3:40 PM • GlobeNewswire
AnaptysBio filed a motion to dismiss Tesaro's anticipatory breach of contract claim in Delaware Chancery Court regarding their Collaboration Agreement over royalties from Jemperli (dostarlimab). Anaptys claims it sought good faith discussions to resolve alleged breaches by Tesaro and GSK, but Tesaro initiated a lawsuit without notice. The court is expected to hear arguments by early March, with trial scheduled for July 14-17, 2026.
01/08/2026, 6:00 PM • GlobeNewswire
GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties
GSK's subsidiary Tesaro has filed a lawsuit against AnaptysBio in Delaware Chancery Court, alleging breach of a license agreement for the cancer drug Jemperli, and seeking to protect its royalty rights.
11/21/2025, 8:48 AM • Benzinga
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
AnaptysBio filed a legal complaint in Delaware Chancery Court against Tesaro and GSK, alleging material breaches of their Collaboration Agreement, specifically related to PD-1 antagonist research and commercial efforts for the drug Jemperli.
11/21/2025, 3:50 AM • GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Multiple health care stocks experienced significant price movements during Monday's after-market trading session, with some companies seeing notable gains while others experienced declines.
09/29/2025, 5:06 PM • Benzinga
Peers
Statistics
MoreInformation as of 10/05/2026
Company Profile
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.